Survodutide and Mazdutide are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Two roads to the same receptor pair
Most of the incretin class is defined by which receptors a molecule engages. Survodutide and Mazdutide are unusual in that they engage exactly the same two — the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) — making them the two leading GLP-1/glucagon dual agonists in metabolic research. What separates them is not the target list but the lineage, the design scaffold and, above all, the research emphasis each programme has chased. If you want the mechanistic detail behind these targets, our explainer on GLP-1 vs GIP vs glucagon agonists unpacks what each receptor actually does. Here we put the two dual agonists directly against each other.
| Survodutide | Mazdutide | |
|---|---|---|
| Class / peptide type | Dual agonist peptide (fatty-acid conjugate) | Dual agonist peptide · oxyntomodulin analogue |
| Receptor targets | GLP-1 + glucagon | GLP-1 + glucagon |
| Developer / code | Boehringer Ingelheim / Zealand Pharma (BI 456906) | Innovent, licensed from Eli Lilly (IBI362 / LY3305677) |
| Duration / schedule | Long-acting · once weekly | Long-acting · once weekly |
| Main research focus | MASH / liver fibrosis (plus obesity) | Weight management (plus type 2 diabetes) |
| Headline trial signal | Ph2 MASH improvement without worsening fibrosis; ~19% weight (Ph2) | ~14.3% mean weight reduction (Ph3 GLORY-1, 48 wk) |
| Regulatory status | Investigational · Phase 3 · FDA Breakthrough Therapy (MASH, 2024) | Investigational · first NDA under NMPA (China) review |
Survodutide: the liver-facing dual agonist
Survodutide (developer code BI 456906) is the product of a collaboration between Boehringer Ingelheim and Denmark's Zealand Pharma. It is a synthetic, fatty-acid-conjugated peptide whose tail promotes reversible binding to serum albumin, giving it the extended, once-weekly duration of action common to the modern incretin class. Mechanistically it does what every GLP-1/glucagon co-agonist does: the GLP-1 arm reduces energy intake through appetite suppression, slowed gastric emptying and glucose-dependent insulin secretion, while the glucagon arm raises energy expenditure and mobilises hepatic lipid.
What has set Survodutide apart is where that second arm points. Its most striking published results are in metabolic dysfunction-associated steatohepatitis (MASH). In a Phase 2 trial in biopsy-confirmed MASH with fibrosis, it improved MASH without worsening fibrosis in a substantial majority of participants on the higher doses versus placebo — data strong enough to earn FDA Breakthrough Therapy designation for MASH in 2024 and to push the compound into a dedicated Phase 3 MASH programme alongside its SYNCHRONIZE obesity trials. It also posted up to roughly 19% mean body-weight reduction in a separate Phase 2 obesity study, so it is by no means a one-note molecule — but the liver signal is its calling card. Researchers can buy Survodutide UK in three strengths, each HPLC tested to ≥99% purity with a COA. The full Survodutide knowledgebase profile covers the trial data in depth.
Mazdutide: the weight-focused oxyntomodulin analogue
Mazdutide (codes IBI362 and LY3305677) took a different design route to the same destination. Rather than engineering a co-agonist from first principles, it is built on the natural oxyntomodulin scaffold — a gut hormone that already activates both the GLP-1 and glucagon receptors, here re-engineered with fatty-acid conjugation for a long, once-weekly duration. It originated in Eli Lilly's incretin programme and is being developed for Greater China by Innovent Biologics, which has driven its late-stage clinical work.
Where Survodutide leads with liver histology, Mazdutide leads with a mature, pivotal weight-management readout. In the Phase 3 GLORY-1 trial in Chinese adults with overweight or obesity, it produced approximately 14.3% mean body-weight reduction at 48 weeks at its higher doses. That trial also carried a notable liver-fat signal — a large majority of participants on the top dose achieved a meaningful reduction in liver fat — so the two compounds are not strangers to each other's territory. Mazdutide has additionally been studied in type 2 diabetes through the DREAMS programme, and its first New Drug Application for chronic weight management is under review by China's NMPA. That makes it, in regulatory terms, the further-along of the two for weight. The Mazdutide knowledgebase profile sets out the GLORY and DREAMS data, and research-grade material is available to buy Mazdutide UK in three strengths with a COA.
What the differences mean in a research context
Read the table across and the surprise is how little separates these two on the mechanism row. Same receptor pair, same long-acting fatty-acid design, same once-weekly schedule, same broad "appetite in, energy out" logic. If you are choosing between them as a controlled probe of GLP-1/glucagon co-agonism, they are close cousins — closer than either is to a GIP-containing agonist such as Tirzepatide or the triple agonist Retatrutide.
The meaningful differences are in origin and emphasis. Survodutide is a purpose-built co-agonist whose standout dataset is hepatic — its Phase 2 MASH results and Breakthrough Therapy status make it the natural reference compound for liver-fat and fibrosis models. Mazdutide is an oxyntomodulin-derived analogue whose standout dataset is a pivotal Phase 3 weight-loss figure, with a regulatory submission already in train in China. So the honest framing is not "which is stronger" but "which question are you asking": for a liver-centric model, Survodutide is the more directly evidenced choice; for a weight-management model with mature Phase 3 grounding, Mazdutide is.
Two caveats researchers should hold onto. First, the headline numbers come from different trials, different populations and different endpoints — Survodutide's MASH result measures liver histology, Mazdutide's GLORY-1 result measures body weight — so they describe different things and cannot be lined up as a ranking. Second, both compounds remain investigational: neither is approved by the MHRA, FDA or any regulator for the uses discussed here, and both are supplied only as research reagents.
The bottom line
Survodutide and Mazdutide are the two flagship GLP-1/glucagon dual agonists, and they hit an identical receptor pair. The split is one of development focus, not target: Survodutide carries the stronger MASH and liver-fibrosis story and an FDA Breakthrough Therapy tag, while Mazdutide carries the more mature weight-management Phase 3 data and a live regulatory filing. For research-grade material, see our dedicated pages to buy Survodutide UK and buy Mazdutide UK, each ≥99% purity with a COA — and pick the one whose evidence base matches the model on your bench.